Genetic polymorphisms and haplotypes of POR, encoding cytochrome P450 Oxidoreductase, in a Japanese population

Drug Metabolism and Pharmacokinetics

Volumn 26, Issue 1, 2011, Pages 107-116

  Saito, Yoshiro ^a   Yamamoto, Noboru ^b   Katori, Noriko ^a   Maekawa, Keiko ^a   Fukushima Uesaka, Hiromi ^a   Sugimoto, Daisuke ^a   Kurose, Kouichi ^a   Sai, Kimie ^a   Kaniwa, Nahoko ^a   Sawada, Jun Ichi ^a,f   Kunitoh, Hideo ^b,g   Ohe, Yuichiro ^b   Yoshida, Teruhiko ^c   Matsumura, Yasuhiro ^d   Saijo, Nagahiro ^e,h   Okuda, Haruhiro ^a   Tamura, Tomohide ^b  

^a NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c NATIONAL CANCER CENTER   (Japan)

^d Research Center for Innovative Oncology   (Japan)

^e NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^f PHARMACEUTICALS AND MEDICAL DEVICES AGENCY   (Japan)

^g MITSUI MEMORIAL HOSPITAL   (Japan)

^h KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Genetic polymorphism; Haplotype; Japanese; Nonsynonymous variation; POR

Indexed keywords

CYTOCHROME P450 REDUCTASE; GENOMIC DNA;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ARTICLE; CONTROLLED STUDY; DNA FLANKING REGION; EXON; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; INTRON; JAPANESE; MAJOR CLINICAL STUDY; MUTATION RATE; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 79952746153     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-10-SC-096     Document Type: Article

References (11)

1. Miller, W. L.: Minireview: regulation of steroidogenesis by electron transfer. Endocrinology, 146: 2544-2550 2005.
2. Fukami, M., Horikawa, R., Nagai, T., Tanaka, Y., Sato, N., Okuyama, T., Nakia, H., Soneda, S., Tachibana, K., Matsuo, N., Sato, S., Homma, K., Nishimura, G., Hasagawa, T. and Ogata, T.: Cytochrame P450 oxidoreducticase gene mutations and Santely-Bixler syndrome with abnormal genitalia and/or impaired sterodogensis: molecular and clinical studies in 10 patients. J. Clin. Endocrinol. Metal., 90: 414-426 (2005)
3. Huang, N., Pandy, A.V., Agarwal, V., Reardon, W., Lapunzina, P. D., Mowat, D., Jabs, E. W., Van Vliet, G., Sack, J., Flück, C. E. and Miller, W. L.: Diversity and function of mutations in p450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis. Am. J. Hum. Genet., 76: 729-749 2005.
4. Homma, K., Hasegawa, T., Nagai, T., Adachi, M., Horikawa, R., Fujiwara, I., Tajima, T., Takeda, R., Fukami, M. and Ogata, T.: Urine steroid hormone profile analysis in cytochrome P450 oxidoreductase deficiency: implication for the backdoor pathway to dihydrotestosterone. J. Clin. Endocrinol. Metab., 91: 2643-2649 2006.
5. Shephard, E. A., Phillips, I. R., Santisteban, I., West, L. F., Palmer, C. N., Ashworth, A. and Povey, S.: Isolation of a human cytochrome P-450 reductase cDNA clone and localization of the corresponding gene to chromosome 7q11.2. Ann. Hum. Genet., 53: 291-301 1989.
6. Gomes, A. M., Winter, S., Klein, K., Turpeinen, M., Schaeffeler, E., Schwab, M. and Zanger, U. M.: Pharmacogenomics of human liver cytochrome P450 oxidoreductase: multifactorial analysis and impact on microsomal drug oxidation. Pharmacogenomics, 10: 579-599 2009.
7. Hart, S. N. and Zhong, X. B.: P450 oxidoreductase: genetic polymorphisms and implications for drug metabolism and toxicity. Expert Opin. Drug Metab. Toxicol., 4: 439-452 2008.
8. Hart, S. N., Li, Y., Nakamoto, K., Wesselman, C. and Zhong, X. B.: Novel SNPs in cytochrome P450 oxidoreductase. Drug Metab. Pharmacokinet., 22: 322-326 2007.
9. Huang, N., Agrawal, V., Giacomini, K. M. and Miller, W. L.: Genetics of P450 oxidoreductase: sequence variation in 842 individuals of four ethnicities and activities of 15missense mutations. Proc. Natl. Acad. Sci. U.S.A., 105: 1733-1738 2008.
10. Agrawal, V., Huang, N. and Miller, W. L.: Pharmacogenetics of P450 oxidoreductase: effect of sequence variants on activities of CYP1A2 and CYP2C19. Pharmacogenet. Genomics, 18: 569-576 2008.
11. Wang, M., Roberts, D. L., Paschke, R., Shea, T. M., Masters, B. S. and Kim, J. J.: Three-dimensional structure of NADPH- cytochrome P450 reductase: prototype for FMN- and FAD- containing enzymes. Proc. Natl. Acad. Sci. U.S.A., 94: 8411-8416 1997.